<!DOCTYPE HTML>
<html lang="zh-Hans">
<head>
    <!--Setting-->
    <meta charset="UTF-8">
	<meta name="referrer" content="never">
    <meta name="viewport" content="width=device-width, user-scalable=no, initial-scale=1.0, maximum-scale=1.0, minimum-scale=1.0">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta http-equiv="Cache-Control" content="no-siteapp">
    <meta http-equiv="Cache-Control" content="no-transform">
    <meta name="renderer" content="webkit|ie-comp|ie-stand">
    <meta name="apple-mobile-web-app-capable" content="TesterTalk --爬虫实践">
    <meta name="apple-mobile-web-app-status-bar-style" content="black">
    <meta name="format-detection" content="telephone=no,email=no,adress=no">
    <meta name="browsermode" content="application">
    <meta name="screen-orientation" content="portrait">
    <link rel="dns-prefetch" href="http://qahome.cn">
    <!--SEO-->

<meta name="description" content="这是一个由爬虫自动生成并维护的网站。"/>



<meta name="keywords" content="爬虫， 自动生成的博客。"/>



<meta name="robots" content="all" />
<meta name="google" content="all" />
<meta name="googlebot" content="all" />
<meta name="verify" content="all" />
    <!--Title-->


<title>电话会议纪要：从疫苗黄金年代看沃森成长空间 | TesterTalk --爬虫实践</title>


    <link rel="alternate" href="/atom.xml" title="TesterTalk --爬虫实践" type="application/atom+xml">


    <link rel="icon" href="/favicon.ico">

    



<link rel="stylesheet" href="/css/bootstrap.min.css?rev=3.3.7">
<link rel="stylesheet" href="/css/font-awesome.min.css?rev=4.5.0">
<link rel="stylesheet" href="/css/style.css?rev=@@hash">




    



    <script>
        var _hmt = _hmt || [];
        (function() {
            var hm = document.createElement("script");
            hm.src = "https://hm.baidu.com/hm.js?true";
            var s = document.getElementsByTagName("script")[0];
            s.parentNode.insertBefore(hm, s);
        })();
    </script>



    
</head>


<!--[if lte IE 8]>
<style>
    html{ font-size: 1em }
</style>
<![endif]-->
<!--[if lte IE 9]>
<div style="ie">你使用的浏览器版本过低，为了你更好的阅读体验，请更新浏览器的版本或者使用其他现代浏览器，比如Chrome、Firefox、Safari等。</div>
<![endif]-->

<body>
    <header class="main-header"  style="background-image:url(http://7xpw2b.com1.z0.glb.clouddn.com/hexo-sinppet/img/banner2.jpg)"  >
    <div class="main-header-box">
        <a class="header-avatar" href="/" title='TesterTalk'>
            <img src="/img/avatar.jpg" alt="logo头像" class="img-responsive center-block">
        </a>
        <div class="branding">
        	<!--<h2 class="text-hide">Snippet主题,从未如此简单有趣</h2>-->
            
                 <img src="/img/branding.png" alt="Snippet 博客主题" class="img-responsive center-block">
            
    	</div>
    </div>
</header>
    <nav class="main-navigation">
    <div class="container">
        <div class="row">
            <div class="col-sm-12">
                <div class="navbar-header"><span class="nav-toggle-button collapsed" data-toggle="collapse" data-target="#main-menu" id="mnav">
                    <span class="sr-only"></span>
                        <i class="fa fa-bars"></i>
                    </span>
                </div>
                <div class="collapse navbar-collapse" id="main-menu">
                    <ul class="menu">
                        
                            <li role="presentation" class="text-center">
                                <a href="/"><i class="fa "></i>首页</a>
                            </li>
                        
                            <li role="presentation" class="text-center">
                                <a href="/categories/今日热点/"><i class="fa "></i>今日热点</a>
                            </li>
                        
                            <li role="presentation" class="text-center">
                                <a href="/categories/科技/"><i class="fa "></i>科技</a>
                            </li>
                        
                            <li role="presentation" class="text-center">
                                <a href="/categories/投资/"><i class="fa "></i>投资</a>
                            </li>
                        
                            <li role="presentation" class="text-center">
                                <a href="/categories/酷软推荐/"><i class="fa "></i>酷软推荐</a>
                            </li>
                        
                            <li role="presentation" class="text-center">
                                <a href="/categories/深度解读/"><i class="fa "></i>深度解读</a>
                            </li>
                        
                            <li role="presentation" class="text-center">
                                <a href="/categories/思维训练/"><i class="fa "></i>思维训练</a>
                            </li>
                        
                            <li role="presentation" class="text-center">
                                <a href="/categories/优秀博客/"><i class="fa "></i>优秀博客</a>
                            </li>
                        
                    </ul>
                </div>
            </div>
        </div>
    </div>
</nav>
    <section class="content-wrap">
        <div class="container">
            <div class="row">
                <main class="col-md-8 main-content m-post">
                    <p id="process"></p>
<article class="post">
    <div class="post-head">
        <h1 id="电话会议纪要：从疫苗黄金年代看沃森成长空间">
            
	            电话会议纪要：从疫苗黄金年代看沃森成长空间
            
        </h1>
        <div class="post-meta">
    
    
    <span class="categories-meta fa-wrap">
        <i class="fa fa-folder-open-o"></i>
        <a href="/categories/投资">
            投资
        </a>
    </span>
    
    
    <span class="fa-wrap">
        <i class="fa fa-tags"></i>
        <span class="tags-meta">
            
                
                    <a href="/tags/雪球" title='雪球'>
                        雪球
                    </a>
                
            
        </span>
    </span>
    

    
        
        <span class="fa-wrap">
            <i class="fa fa-clock-o"></i>
            <span class="date-meta">2018/06/10</span>
        </span>
    
</div>

            
            
    </div>
    
    <div class="post-body post-content">
        <p><a href="http://xueqiu.com/n/%E4%BB%8A%E6%97%A5%E8%AF%9D%E9%A2%98" target="_blank" rel="noopener">@今日话题</a> <br><br><strong>公司在新型疫苗和单抗研发领域处领先地位 </strong><br><br>公司是一家专业从 事人用疫苗<h-char unicode="\"3001\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>、</h-inner></h-char>单抗药物等生物药并且集研<h-char unicode="\"3001\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>、</h-inner></h-char>产<h-char unicode="\"3001\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>、</h-inner></h-char>销一体化的创新型高科技生物制药企业<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char> 在新型疫苗和单抗药物两大细分领域处于行业领先地位<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char> <br><br>生物药行业<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>重磅产品的上市是公司业绩的有力保证<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>沃森生 物对研发一直保持较高的投入<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>2010-2016 年研发费用 CAGR 达 47%<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>2017 年研发投 入 3.3 亿元<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>占营业收入达 49%<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>在医药行业中研发收入占比最高<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>同时<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>公司核心管 理团队由来自国家队的创业团队和具有海外跨国公司从业背景的专业团队组成<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>创新能 力卓越<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>公司拥有博士<h-char unicode="\"3001\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>、</h-inner></h-char>硕士学位 100 余人<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>高端海归科学家 15 人<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>中组部<h-char unicode="\"201c\"" class="\"biaodian" cjk="" bd-open="" punct\"="">“</h-char>千人计 划<h-char unicode="\"201d\"" class="\"biaodian" cjk="" bd-close="" bd-end="" punct\"="">”</h-char>专家 3 人<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char> <br><br><strong>公司研发投入占比不断提高 </strong><br><br><strong>产品储备丰富<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>国内生物药布局最全 </strong><br><br>传统疫苗板块<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>沃森有 3 个疫苗处于临床试验<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>其中 13 价肺炎疫苗已完成 III 期临床数 据总结申报生产<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>并进入了优先评审程序<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>预计最快今年四季度将上市<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>进度国内领先<h-char unicode="\"ff1b\"" class="\"biaodian" cjk="" bd-end="" bd-jiya\"=""><h-inner>；</h-inner></h-char> 新型疫苗板块<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>有 2 个疫苗处于临床试验<h-char unicode="\"ff1b\"" class="\"biaodian" cjk="" bd-end="" bd-jiya\"=""><h-inner>；</h-inner></h-char>在单抗板块<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>沃森已有 7 个单抗药物处于临 床试验阶段<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>其中赫赛汀和类克为国内首仿<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>均处于 III 期临床.<strong><br></strong><br><strong>核心产品 13 价肺炎结合疫苗<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>国内市场万众瞩目</strong><br> 13 价肺炎多糖结合疫苗<h-char unicode="\"ff08\"" class="\"biaodian" cjk="" bd-open="" bd-jiya\"=""><h-inner>（</h-inner></h-char>PCV-13<h-char unicode="\"ff09\"" class="\"biaodian" cjk="" bd-close="" bd-end="" bd-jiya\"=""><h-inner>）</h-inner></h-char>被称为全球<h-char unicode="\"201c\"" class="\"biaodian" cjk="" bd-open="" punct\"="">“</h-char>疫苗之王<h-char unicode="\"201d\"" class="\"biaodian" cjk="" bd-close="" bd-end="" punct\"="">”</h-char><h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>是研发难度最大的疫苗<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char> 它含有 13 个血清型<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>研发难度远高于 13 个单位的多糖疫苗<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>惠氏公司最先将肺炎链球菌多糖与 CRM-197 载体蛋白结合研发出 7 价 肺炎结合疫苗给儿童使用<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>并成为惠氏 13 价肺炎多糖结合疫苗研发成功的基础<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char><br>沃森生物 PCV-13 已经揭盲<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>临床结果在各项指标对比中不劣于辉瑞的 PCV-13<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>达到了预设的临床试验终 点<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>公司生产车间已经完备<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>以优先评审身份进入了报生产阶段<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>预计最快将在今年四 季度获批上市<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>成为全球第二家<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>国内第一家拥有 PCV-13 重磅品种的厂家<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>国内除沃森外申报 PCV-13 的厂家还有北京民海<h-char unicode="\"3001\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>、</h-inner></h-char>北京科兴<h-char unicode="\"3001\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>、</h-inner></h-char>兰州所<h-char unicode="\"3001\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>、</h-inner></h-char>成都安特金和武汉博沃<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char> 北京民海虽然进入临床时间比沃森早 1 年半<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>但在临床进度上却落后于沃森<br><br><strong>国内在研 PCV-13 进度 </strong><br><br>PCV-13 被称为<h-char unicode="\"201c\"" class="\"biaodian" cjk="" bd-open="" punct\"="">“</h-char>疫苗之王<h-char unicode="\"201d\"" class="\"biaodian" cjk="" bd-close="" bd-end="" punct\"="">”</h-char><h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>不仅因为其研发难度大<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>也因为其市场空间大<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>销售峰值高<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char> 肺炎球菌感染是导致严重疾病如脑膜炎<h-char unicode="\"3001\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>、</h-inner></h-char>菌血症<h-char unicode="\"3001\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>、</h-inner></h-char>肺炎等的主要致病因子<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>同时也是鼻 窦炎<h-char unicode="\"3001\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>、</h-inner></h-char>中耳炎等常见病的致病因子之一<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>肺炎球菌感染是全球儿童及成年人致病<h-char unicode="\"3001\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>、</h-inner></h-char>致死 的重要原因之一<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>根据 WHO资料<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>全球每年有约 160 万人死于肺炎 球菌疾病<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>其中大多数是婴儿和老人<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>在全球疫苗可预防疾病中<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>肺炎球菌疾病是导致 5 岁以下儿童死亡的首位原因<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>肺炎位于中国五岁以下儿童死因的第二位<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char><br>PCV-13 目前已经进入全球 100 多个国家的免疫规划中<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>是全球使用最为广泛的肺炎球 菌多糖结合疫苗<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>2016 年全球销售 57 亿美元<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>位列全球重磅产品第十位<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>2017 年以 56 亿美金位居全球销售第 11 位.<br>辉瑞 PCV-13 全球销售额<h-char unicode="\"ff08\"" class="\"biaodian" cjk="" bd-open="" bd-jiya\"=""><h-inner>（</h-inner></h-char>百万美元<h-char unicode="\"ff09\"" class="\"biaodian" cjk="" bd-close="" bd-end="" bd-jiya\"=""><h-inner>）</h-inner></h-char> <br><br>13 价肺炎结合疫苗全球销售将继续火爆<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>13 价肺炎结合疫苗是目前唯一一款用于全年龄组人群注射的肺炎疫苗<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>全球近年持续销售火爆<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>随着适龄人群的增加<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>16 年达到 57 亿美元销售额<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>随着新获批适龄人群的陆续放量<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>我们预计 13 价肺炎在全球的销售将 会持续火爆<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char> 我国近年每年新生儿达 1600-1700 万<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>全面二孩政策后虽然人口增速没有达到预期效果<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char> 据彭博新闻称今年之内将有可能全面放开计划生育<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>预计我国每年的新生儿人口可能达 到 1800-2000 万<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char><br>我国儿童肺炎领域仅有供 2 岁以上儿童接种的 23 价肺炎疫苗.针对 2 岁以下婴幼儿的肺炎疫苗市场长期处于空白状态<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>辉瑞的 13 价沛儿 2016 年底获批进入 中国<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>2017 年共签发 71 万支<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>截止目前为止<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>共批签发 143 万支<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>不 到 48 万人份<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>全国各地严重缺货<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>公司的 13 价肺炎疫苗将是继辉瑞之后国内首家上市 的国产 13 价肺炎结合疫苗<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>竞争优势明显<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>且其适用范围是 6 周-5 岁龄<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>比辉瑞的接 种范围更广<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>另一方面<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>辉瑞 PCV-13 有特定的免疫程序<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>2,4,6 月龄假设公司上市后的 售价参考辉瑞当前售价 700 元/支<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>保守估计接种率只有 1%的情形下<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>国内 PCV-13 的 总需求量达到 564 万支<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>辉瑞批签发的 143 万支只能满足 25%的市场需求<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char><br>沃森生物已 构建了一个覆盖国内 30 个省市<h-char unicode="\"3001\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>、</h-inner></h-char>2000 多个县区的营销网络<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>假设其 PCV-13 市占率分 别达到 20%<h-char unicode="\"3001\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>、</h-inner></h-char>40%<h-char unicode="\"3001\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>、</h-inner></h-char>60%的情况下<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>能给公司带来 7.9<h-char unicode="\"3001\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>、</h-inner></h-char>15.8<h-char unicode="\"3001\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>、</h-inner></h-char>23.7 亿元收入<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>当公司 产品进入稳定期<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>每年能带来净利润 10 亿元以上.<br><br><strong>二价 HPV 疫苗接力 PCV13 成另一款 10 亿级重磅产品 </strong><br>目前全球范围内已上市的 HPV 疫苗产品有三种<h-char unicode="\"ff1a\"" class="\"biaodian" cjk="" bd-end="" bd-jiya\"=""><h-inner>：</h-inner></h-char>默沙东的 Gardasil(四价 HPV 疫苗)和 Gardasil 9(九价 HPV 疫苗)以及 GSK 公司的 Cervarix(16/18 型二价 HPV 疫苗)<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>HPV 疫 苗自 2006 年上市以来<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>已在全球 136 个国家和地区销售<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>近几年来每年销售额在 20 亿 美金左右<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>其中默沙东两个产品占整个 HPV 疫苗市场的 95%左右<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>处于绝对垄断地位<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char> <br><br>沃森生物二价 HPV 疫苗目前处于临床 III 期后期<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>处于收集分析临床结果判定终点病例 样本的最后阶段<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>沃森的临床试验方案同时满足癌前病变和抗持续感染两种临床终点要 求<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>并且在现行的癌前病变临床终点的要求下<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>优势十分明显<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>二价 HPV 疫苗如仍然以 癌前病变作为三期临床终点不改变的话<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>预计今年上半年结束临床试验<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>2019 年即将上 市<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char><br><br>HPV 疫苗的最佳接种年龄是 11-12 岁<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>美国推荐 9-26 岁接种<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>默沙东在美国的说明书 接种年龄为 9-26 岁<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>四价在中国的说明书接种年龄为 20-45 岁<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>九价在中国的接种年龄 是 16-26 岁<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>沃森的产品说明书规定接种年龄为 9-30 岁<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>对比默沙东四价<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>从接种年龄 人群来看<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>默沙东接种人群为 20-45 岁<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>而沃森接种年龄为 9-30 岁<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>未来在低年龄人群 上将是推广重点<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>而对比默沙东九价 HPV<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>二价价格是其一半不到<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>将是一大优势<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>对 比 GSK 二价 HPV<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>其目前基本采用网上预约销售模式<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>销售推广能力较弱<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>沃森自身 优势明显<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char><br>2007 年<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>沃森 Hib 疫苗上市<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>国外厂家有巴斯德<h-char unicode="\"3001\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>、</h-inner></h-char>葛兰素史克<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>2010 年沃 森 Hib 疫苗市场占有率居第一位<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>其强大的销售能力可见一斑<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char> 另外国内市场适龄女性人群较多<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>按 2016 年中国统计年鉴数据<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>中国 9-30 岁女性人群 在 1.75 亿左右<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>按照目前每人份 1800 元计算<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>市场规模巨大<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>足够容纳几家企业<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>庞 大的市场不可能独吞<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>进口疫苗商的市场教育和学术推广能力强<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>先期市场培育意义非 凡<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char>进口产品的获批也有利于中国的生产企业<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>一方面进口疫苗的上市会加快国产疫苗 的获批进程<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>另一方面进口疫苗厂商对国内市场规范<h-char unicode="\"3001\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>、</h-inner></h-char>学术推广等工作具有卓越的能力 和长足的经验<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>有利于进一步规范国内市场<h-char unicode="\"3002\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>。</h-inner></h-char> <br><br><strong>沃森二价 HPV 销售额预测 </strong><br><br><a href="http://xueqiu.com/S/SZ300142" target="_blank" rel="noopener">$沃森生物(SZ300142)$</a> <a href="http://xueqiu.com/S/SZ300601" target="_blank" rel="noopener">$康泰生物(SZ300601)$</a> <a href="http://xueqiu.com/S/SZ300122" target="_blank" rel="noopener">$智飞生物(SZ300122)$</a> <br><br><strong>微信2696884654</strong><br><strong>调研君,一**</strong>枚机构分析师<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char><strong><strong>希望结识更多志同道合投资者一起研究公司<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char></strong></strong>关注该内容可以<strong>**和作者交流<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>共同深入研究公司和行业基本面信息<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>希望结识更多志同道合投资者一起研究公司<h-char unicode="\"ff0c\"" class="\"biaodian" cjk="" bd-end="" bd-cop="" bd-hangable="" bd-jiya\"=""><h-inner>，</h-inner></h-char>备注球友</strong><br>原文请参见: <a href="https://xueqiu.com/3776858059/108623051" target="_blank" rel="noopener">https://xueqiu.com/3776858059/108623051</a> </p>

    </div>

    <div class="post-footer">
        <div>
            
                转载声明：商业转载请联系作者获得授权,非商业转载请注明出处 © <a href="" target="_blank">Snippet</a>
            
        </div>
        <div>
            
        </div>
    </div>
</article>

<div class="article-nav prev-next-wrap clearfix">
    
        <a href="/2018/06/10/白话流动性危机/" class="pre-post btn btn-default" title='白话流动性危机'>
            <i class="fa fa-angle-left fa-fw"></i><span class="hidden-lg">上一篇</span>
            <span class="hidden-xs">白话流动性危机</span>
        </a>
    
    
        <a href="/2018/06/10/归去来兮，独角兽/" class="next-post btn btn-default" title='归去来兮，独角兽'>
            <span class="hidden-lg">下一篇</span>
            <span class="hidden-xs">归去来兮，独角兽</span><i class="fa fa-angle-right fa-fw"></i>
        </a>
    
</div>


    <div id="comments">
        
   <p>评论系统未开启，无法评论！</p>

    </div>





                </main>
                
    <aside class="col-md-4 sidebar">
        
        
    <div class="widget">    
        <h3 class="title">Search</h3>
        <div id="search-form">
            <div id="result-mask" class="hide"></div>
            <div class="search-area">
                
                    <input id="search-key" type="search" autocomplete="off" placeholder="搜点什么呢?">
                    <button type="button" class="search-form-submit" id="search-local">站内搜索</button>
                
                
            </div>
            <div id="result-wrap" class="hide">
                <div id="search-result"></div>
            </div>
            <div class="hide">
                <template id="search-tpl">
                    <div class="item">
                        <a href="/{path}" title="{title}">
                            <div class="title">{title}</div>
                            <div class="content">{content}</div>
                        </a>
                    </div>
                </template>
            </div>
        </div>
    </div>

        
        
    <div class="widget notification">
        <h3 class="title">网站公告</h3>
        <div>
            <p><b>本站一切内容摘自网络，完全由爬虫自动生成，维护，本站目的为了学以致用，如所发布文章侵犯了您的权益，请联系公众号 TesterTalk.</b> <br/>
</p>
        </div>
    </div>

        
        
    <div class="widget">
      <h3 class="title">Social</h3> 
        <div class="content social">
            
	            <a href="//github.com/Light07/autoblog.git" rel="external nofollow" title="Github" target="_blank">
			    	<i class="git fa fa-git"></i>
			    </a>
            
	            <a href="//www.zhihu.com/people/thinkbig" rel="external nofollow" title="知乎" target="_blank">
			    	<i class="user fa fa-user"></i>
			    </a>
            
        </div>
    </div>


        
        
    <div class="widget">
        <h3 class="title">Categories</h3>
        <ul class="category-list"><li class="category-list-item"><a class="category-list-link" href="/categories/今日热点/"><i class="fa" aria-hidden="true">今日热点</i></a><span class="category-list-count">144</span></li><li class="category-list-item"><a class="category-list-link" href="/categories/优秀博客/"><i class="fa" aria-hidden="true">优秀博客</i></a><span class="category-list-count">2</span></li><li class="category-list-item"><a class="category-list-link" href="/categories/思维训练/"><i class="fa" aria-hidden="true">思维训练</i></a><span class="category-list-count">3</span></li><li class="category-list-item"><a class="category-list-link" href="/categories/投资/"><i class="fa" aria-hidden="true">投资</i></a><span class="category-list-count">18</span></li><li class="category-list-item"><a class="category-list-link" href="/categories/深度解读/"><i class="fa" aria-hidden="true">深度解读</i></a><span class="category-list-count">8</span></li><li class="category-list-item"><a class="category-list-link current" href="/categories/科技/"><i class="fa" aria-hidden="true">科技</i></a><span class="category-list-count">77</span></li><li class="category-list-item"><a class="category-list-link" href="/categories/酷软推荐/"><i class="fa" aria-hidden="true">酷软推荐</i></a><span class="category-list-count">26</span></li></ul>
    </div>


        
        
    <div class="widget">
      <h3 class="title">Archives</h3>
        <ul class="archive-list"><li class="archive-list-item"><a class="archive-list-link" href="/archives/2018/08/"><i class="fa" aria-hidden="true">August 2018</i></a><span class="archive-list-count">25</span></li><li class="archive-list-item"><a class="archive-list-link" href="/archives/2018/07/"><i class="fa" aria-hidden="true">July 2018</i></a><span class="archive-list-count">222</span></li><li class="archive-list-item"><a class="archive-list-link" href="/archives/2018/06/"><i class="fa" aria-hidden="true">June 2018</i></a><span class="archive-list-count">28</span></li><li class="archive-list-item"><a class="archive-list-link" href="/archives/2018/05/"><i class="fa" aria-hidden="true">May 2018</i></a><span class="archive-list-count">3</span></li></ul>
    </div>


        
        
  <div class="widget">
    <h3 class="title">Tag Cloud</h3>
    <div class="content tag-cloud">
        <a href="/tags/卢松松博客/" style="font-size: 13.33px;">卢松松博客</a> <a href="/tags/小众软件/" style="font-size: 16.67px;">小众软件</a> <a href="/tags/战隼的学习探索/" style="font-size: 11.67px;">战隼的学习探索</a> <a href="/tags/知乎日报/" style="font-size: 20px;">知乎日报</a> <a href="/tags/酷-壳-–-CoolShell/" style="font-size: 10px;">酷 壳 – CoolShell</a> <a href="/tags/雪球/" style="font-size: 15px;">雪球</a> <a href="/tags/雷锋网/" style="font-size: 18.33px;">雷锋网</a>
    </div>
  </div>


        
        
    <div class="widget">
        <h3 class="title">Friends</h3>
        <div class="content friends-link">
        
            <a href="http://www.helloqa.com" class="fa" target="_blank">TesterTalk软件测试分享</a>
        
        </div>
    </div>


        
    </aside>

            </div>
        </div>
    </section>
    <footer class="main-footer">
    <div class="container">
        <div class="row">
        </div>
    </div>
</footer>

<a id="back-to-top" class="hide">
	<i class="fa fa-chevron-up"></i>
</a>




    <div class="copyright">
    <div class="container">
        <div class="row">
            <div class="col-sm-12"> 
                <span>Copyright &copy; 2018
                </span> | 
                <span>
                    Powered by <a href="//hexo.io" class="copyright-links" target="_blank" rel="nofollow">Hexo</a>
                </span> | 
                <span>
                    Theme by <a href="//github.com/shenliyang/hexo-theme-snippet.git" class="copyright-links" target="_blank" rel="nofollow">Snippet</a>
                </span>
            </div>
        </div>
    </div>
</div>



	<script src="/js/search.js?rev=@@hash"></script>


<script src="/js/app.js?rev=@@hash"></script>


</body>
</html>